Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Crit Care ; 9(5): R508-15, 2005 Oct 05.
Artigo em Inglês | MEDLINE | ID: mdl-16277712

RESUMO

INTRODUCTION: The aim of this study was to assess the efficacy of two dosing schedules of recombinant human erythropoietin (rHuEPO) in increasing haematocrit (Hct) and haemoglobin (Hb) and reducing exposure to allogeneic red blood cell (RBC) transfusion in critically ill patients. METHOD: This was a prospective, randomized, multicentre trial. A total of 13 intensive care units participated, and a total of 148 patients who met eligibility criteria were enrolled. Patients were randomly assigned to receive intravenous iron saccharate alone (control group), intravenous iron saccharate and subcutaneous rHuEPO 40,000 units once per week (group A), or intravenous iron saccharate and subcutaneous rHuEPO 40,000 units three times per week (group B). rHuEPO was given for a minimum of 2 weeks or until discharge from the intensive care unit or death. The maximum duration of therapy was 3 weeks. RESULTS: The cumulative number of RBC units transfused, the average numbers of RBC units transfused per patient and per transfused patient, the average volume of RBCs transfused per day, and the percentage of transfused patients were significantly higher in the control group than in groups A and B. No significant difference was observed between group A and B. The mean increases in Hct and Hb from baseline to final measurement were significantly greater in group B than in the control group. The mean increase in Hct was significantly greater in group B than in group A. The mean increase in Hct in group A was significantly greater than that in control individuals, whereas the mean increase in Hb did not differ significantly between the control group and group A. CONCLUSION: Administration of rHuEPO to critically ill patients significantly reduced the need for RBC transfusion. The magnitude of the reduction did not differ between the two dosing schedules, although there was a dose response for Hct and Hb to rHuEPO in these patients.


Assuntos
Transfusão de Sangue/estatística & dados numéricos , Eritrócitos/efeitos dos fármacos , Eritropoetina/administração & dosagem , Hemoglobinas/efeitos dos fármacos , Adulto , Idoso , Idoso de 80 Anos ou mais , Relação Dose-Resposta a Droga , Métodos Epidemiológicos , Feminino , Humanos , Ferro/uso terapêutico , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes , Fatores de Tempo
2.
Intensive Care Med ; 28(9): 1351-6, 2002 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12209289

RESUMO

OBJECTIVES: To define the role of procalcitonin in the differential diagnosis, prognosis and follow-up of critically ill patients. DESIGN: Prospective study during the 2-year period from January 1998-2000. PATIENTS: One hundred nineteen critically ill patients: 29 with systemic inflammatory response syndrome (SIRS) without any signs of infection, 11 with sepsis, 17 with severe sepsis, 10 with septic shock and 52 controls. Daily measurements of procalcitonin were performed by an immunocheminoluminometric assay, and values were correlated to the clinical characteristics of the patients. RESULTS: Mean concentrations of procalcitonin were 5.45 (95% CI: 2.11, 8.81), 7.29 (95% CI: -1.92,14.59), 6.26 (95% CI: -1.32, 13.85) and 38.76 ng/ml (95% CI: 0.15, 77.38) on the 1st day in patients with SIRS, sepsis, severe sepsis and septic shock, respectively, and were statistically superior to those of control patients. Procalcitonin was gradually diminished over time with the resolution of the syndrome, while it was sustained in the same or more augmented levels upon worsening. Mean concentrations of procalcitonin on the 1st day for patients finally progressing to ARDS, to ARDS and acute renal failure, to ARDS, acute renal failure and DIC and to ARDS, acute renal failure, DIC and hepatic failure were 10.48, 8.08, 32.72 and 43.35 ng/ml, respectively. ROC curves of the sensitivity and specificity of procalcitonin for the evaluation of SIRS and sepsis were similar. CONCLUSIONS: The definite differential diagnosis between SIRS and sepsis may not rely on a single application of procalcitonin but on the complete clinical and laboratory evaluation of the patient with procalcitonin playing a considerable role. Procalcitonin is an early prognostic marker of the advent of MODS; therefore, daily determinations might help in the follow-up of the critically ill patient.


Assuntos
Biomarcadores , Calcitonina , Precursores de Proteínas , Síndrome de Resposta Inflamatória Sistêmica/diagnóstico , Idoso , Idoso de 80 Anos ou mais , Calcitonina/sangue , Peptídeo Relacionado com Gene de Calcitonina , Estado Terminal , Diagnóstico Diferencial , Feminino , Grécia , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Prospectivos , Precursores de Proteínas/sangue , Curva ROC , Síndrome de Resposta Inflamatória Sistêmica/sangue
4.
J Morphol ; 198(1): 83-93, 1988 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-29898570

RESUMO

Larval salivary gland cells of seven Drosophila species from the melanogaster group were studied during the early third-instar period. Similar cytoplasmic organization was seen in both the distal and proximal parts of the gland. The cytoplasm contained a large number of free ribosomes, but only a few rough endoplasmic reticulum profiles; the nucleolus was very large. Golgi complexes consisted mainly of vesiculated cisternae. Small secretory granules (diameter, 0.23-0.32 µm) are produced during this period and in some species contain both granular and filamentous material. These granules appeared to be secreted by a peculiar "apocrine-type" secretion after enclosure of granules into microvillar "lacunae." A digestive function is attributed to the secretory material. During the third instar, a close association between the salivary gland and the fat body also was observed. The physiological significance of this association seems to be related to the transfer of nutrients, enzymes, or membranous materials from fat body to salivary gland.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA